Antidepressant side effects and their impact on treatment outcome in people with major depressive disorder: an iSPOT-D report

Braund, Taylor A; Tillman, Gabriel; Palmer, Donna M.; Gordon, Evian; Rush, A. John; Harris, Anthony

doi:10.1038/s41398-021-01533-1

Cited by 55 publications

(37 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Practitioners may see MC as a viable treatment option, even with limited or ambiguous clinical evidence of efficacy or as last resort treatment when all other conventional treatments have failed ( Hallinan et al, 2021 ). This may be the case with pain and mental and behavioral disorders in particular, where there has been ever-expanding clinical need, and a high side-effect burden with conventional prescribing options ( Deloitte Access Economics, 2019 ; Braund et al, 2021 ; Painaustralia, 2021 ).…”

Section: Discussionmentioning

confidence: 99%

Medicinal Cannabis Prescribing in Australia: An Analysis of Trends Over the First Five Years

et al. 2022

View full text Add to dashboard Cite

A regulatory framework allowing legal access to medicinal cannabis (MC) products has operated in Australia since November 2016. MC prescribing by healthcare practitioners (HCPs) is primarily conducted through the Special Access Scheme - Category B (SAS-B) pathway, through which prescribers apply to the Therapeutic Goods Administration (TGA–the federal regulator) for approval to prescribe a category of product to an individual patient suffering from a specific indication. The dataset collected by the TGA provides a unique opportunity to examine MC prescribing trends over time in the Australian population. Here we analysed this TGA SAS-B dataset since inception with respect to age, gender, product type (e.g., oil, flower, etc.), CBD content, indication treated, and prescriber location. Results are presented descriptively as well as being analysed using non-linear regression models. Relationship between variables were explored via correspondence analyses. Indications were classified with reference to the International Statistical Classification of Diseases and Related Health Problems (10th Revision). As of 31 August 2021, a total of 159,665 SAS-B approvals had been issued for MC products, 82.4% of were since January 2020. Leading indications for approvals were for pain, anxiety, and sleep disorders. Oil products were the most popular product type, while CBD-dominant products (≥98% CBD) accounted for 25.1% of total approvals. Approvals for flower products increased markedly during 2020–2021, as did approvals involving younger age groups (18–31 years old), male patients, and non-CBD dominant products. A disproportionate number of SAS-B MC applications (around 50%) came from HCPs in the state of Queensland. Associations between patient gender and age and/or indication with product type were found. For example, approvals for oil products were commonly associated with approvals for pain. While, overall prescribing increased dramatically over the last 2 years of analysis, stabilization of approval numbers is evident for some indications, such as pain. Current prescribing practices do not always reflect provided TGA guidance documents for MC prescribing. While acknowledging some limitations around the SAS-B dataset, it provides a unique and valuable resource with which to better understand current prescribing practices and utilisation of MC products within Australia.

show abstract

Section: Discussionmentioning

confidence: 99%

Medicinal Cannabis Prescribing in Australia: An Analysis of Trends Over the First Five Years

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Pharmacological treatments are efficacious for reducing depressive symptoms [ 9 ]. Still, they have many side effects, including falls, fractures, and an increased risk of premature death [ 10 ]. Moreover, antidepressant users appeared to be at the highest risk of becoming frail [ 11 ].…”

Section: Introductionmentioning

confidence: 99%

Prevalence of Frailty and Its Association with Depressive Symptoms among European Older Adults from 17 Countries: A 5-Year Longitudinal Study

Marconcin

Barak

Ferrari

et al. 2022

IJERPH

View full text Add to dashboard Cite

Background: This study aimed to examine the association between frailty and depressive symptoms. Methods: Cross-sectional and five-year longitudinal study. Data were from the population-based Survey of Health, Aging, and Retirement in Europe (SHARE) waves six (2015) and eight (2020). Frailty was assessed using the SHARE-Frailty Instrument. Fatigue, appetite, walking difficulties, and physical activity were self-reported, and grip strength was measured using a handgrip dynamometer. The EURO-D 12-item scale was used to measure depressive symptoms. Results: The sample comprised 25,771 older adults (56.2% female) with a mean age of 66.5 (95% CI 66.4, 66.6) years. The prevalence of frailty was 4.2% (95% CI 3.9, 4.4) in 2015 and 6.7% (95% CI 13.5, 14.3) in 2020. Among frail participants, 72.5% and 69.6% had depression in 2015 and 2020, respectively. Frailty was associated with depression over the 5 years. Those with pre-frailty and those with frailty in 2015 had 1.86 (95% CI 1.71, 2.01) and 2.46 (95% CI 2.14, 2.83) greater odds of having depressive symptoms in 2020. Conclusions: Frailty is a predictor of depression in older adults, and frail participants had greater odds of presenting depressive symptoms.

show abstract

“…It has been reported greater use of traditional medicine more than 2 fold in individuals affected by a mental disorder (52.9%) compared to people without a mental disorder (22.1%), in depression or anxiety where prevalence is higher in women, being those who use it for self-help more than men. Severity of side effects over the course of treatment with antidepressant or anxiolytic medications is an important factor that causes people to give up pharmacological treatment, mainly those suffering comorbidly, where the time of treatment and response play an important role ( Braund et al, 2021 ). Antidepressant activity is recognized in Salvia species from subgenus Calosphace such as S. elegans ( Mora et al, 2006 ) due to the compound 5-O-(6-rhamnosylglucoside)-7-hydroxy-4′-methoxyflavanone ( González-Cortazar et al, 2013 ) using the forced swimming test.…”

Section: Resultsmentioning

confidence: 99%

A Review on the Ethnopharmacology and Phytochemistry of the Neotropical Sages (Salvia Subgenus Calosphace; Lamiaceae) Emphasizing Mexican Species

et al. 2022

View full text Add to dashboard Cite

Salvia is the most diverse genus within the mint family (Lamiaceae), many of its species are well-known due to their medicinal and culinary uses. Most of the ethnopharmacological and phytochemical studies on Salvia are centred on species from the European and Asian clades. However, studies about the most diverse clade, the Neotropical sages (Salvia subgenus Calosphace; 587 spp.), are relatively scarce. This review aims to compile the information on the traditional medicinal uses, pharmacological and phytochemistry properties of the Neotropical sages. To do so, we carried out a comprehensive review of the articles available in different online databases published from the past to 2022 (i.e., PubMed, Scopus, and Web of Science, among others) and summarized the information in tables. To uncover phylogenetic patterns in the distribution of four different groups of metabolites (mono-, sesqui-, di-, and triterpenes), we generated presence-absence matrices and plotted the tip states over a dated phylogeny of Salvia. We found several studies involving Mexican species of Salvia, but only a few about taxa from other diversity centres. The main traditional uses of the Mexican species of Calosphace are medicinal and ceremonial. In traditional medicine 56 species are used to treat diseases from 17 categories according to the WHO, plus cultural-bound syndromes. Pharmacological studies reveal a wide range of biological properties (e.g., antinociceptive, anti-inflammatory, anxiolytic, cytotoxic, and antidiabetic, etc.) found in extracts and isolated compounds of 38 Neotropical sages. From extracts of these species, at least 109 compounds have been isolated, identified and evaluated pharmacologically; 73 of these compounds are clerodanes, 21 abietanes, six flavonoids, five sesquiterpenoids, and four triterpenoids. The most characteristic metabolites found in the Neotropical sages are the diterpenes, particularly clerodanes (e.g., Amarisolide A, Tilifodiolide), that are found almost exclusively in this group. The Neotropical sages are a promising resource in the production of herbal medication, but studies that corroborate the properties that have been attributed to them in traditional medicine are scarce. Research of these metabolites guided by the phylogenies is recommended, since closely related species tend to share the presence of similar compounds and thus similar medicinal properties.

show abstract

Antidepressant side effects and their impact on treatment outcome in people with major depressive disorder: an iSPOT-D report

Cited by 55 publications

References 32 publications

Medicinal Cannabis Prescribing in Australia: An Analysis of Trends Over the First Five Years

Medicinal Cannabis Prescribing in Australia: An Analysis of Trends Over the First Five Years

Prevalence of Frailty and Its Association with Depressive Symptoms among European Older Adults from 17 Countries: A 5-Year Longitudinal Study

A Review on the Ethnopharmacology and Phytochemistry of the Neotropical Sages (Salvia Subgenus Calosphace; Lamiaceae) Emphasizing Mexican Species

Contact Info

Product

Resources

About